![What you need to know before you go to Sea Air Space 2025 [VIDEO]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/05/Screen-Shot-2024-05-14-at-12.19.19-PM.png?#)
.jpg)
New research finds novel drug target for acute myeloid leukemia
A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly blood cancer with a five-year survival rate of just 30%, according to the National Cancer Institute. Their study, published in Cell Stem Cell in February, highlights the crucial role of a protein called paraspeckle component 1 (PSPC1) in the progression of AML.
A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly blood cancer with a five-year survival rate of just 30%, according to the National Cancer Institute. Their study, published in Cell Stem Cell in February, highlights the crucial role of a protein called paraspeckle component 1 (PSPC1) in the progression of AML.
